US 11,667,685 B2
B*44 restricted peptides for use in immunotherapy against cancers and related methods
Colette Song, Tuebingen (DE); Heiko Schuster, Tuebingen (DE); Daniel Johannes Kowalewski, Tuebingen (DE); Oliver Schoor, Tuebingen (DE); Jens Fritsche, Tuebingen (DE); Toni Weinschenk, Tuebingen (DE); and Harpreet Singh, Tuebingen (DE)
Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on Sep. 2, 2022, as Appl. No. 17/929,465.
Application 17/929,465 is a continuation of application No. 16/571,982, filed on Sep. 16, 2019.
Claims priority of provisional application 62/732,300, filed on Sep. 17, 2018.
Claims priority of application No. 10 2018 122 623.3 (DE), filed on Sep. 17, 2018.
Prior Publication US 2023/0002464 A1, Jan. 5, 2023
Int. Cl. C07K 14/47 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 14/725 (2006.01); C07K 14/74 (2006.01); C07K 16/18 (2006.01); C12N 5/0783 (2010.01); C12Q 1/6886 (2018.01); C07K 7/04 (2006.01); A61K 38/08 (2019.01); C07K 7/06 (2006.01); G16B 25/10 (2019.01)
CPC C07K 14/4748 (2013.01) [A61K 35/17 (2013.01); A61K 39/0011 (2013.01); C07K 14/7051 (2013.01); C07K 14/70539 (2013.01); C07K 16/18 (2013.01); C12N 5/0636 (2013.01); C12Q 1/6886 (2013.01); A61K 38/08 (2013.01); C07K 7/04 (2013.01); C07K 7/06 (2013.01); C07K 2319/00 (2013.01); C07K 2319/55 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G16B 25/10 (2019.02)] 20 Claims
 
1. A method of treating a patient who has prostate cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of EENIVAIGI (SEQ ID NO: 11).